Get the Stockscreener App
75.65
0.17%
0.13
Pre-market:
75.57
-0.08
-0.11%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $75.65, with a volume of 6.53M.
It is up +0.17% in the last 24 hours and up +7.95% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$75.52
Open:
$75.485
24h Volume:
6.53M
Relative Volume:
1.27
Market Cap:
$234.54B
Revenue:
$54.07B
Net Income/Loss:
$7.04B
P/E Ratio:
33.55
EPS:
2.255
Net Cash Flow:
$7.28B
1W Performance:
+1.46%
1M Performance:
+7.95%
6M Performance:
-13.26%
1Y Performance:
+14.05%
1-Day Range:
$75.34
$76.11
1-Week Range:
$73.54
$76.25
52-Week Range:
$62.75
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
75.65 | 234.54B | 54.07B | 7.04B | 7.28B | 2.255 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
AstraZeneca Partnership Opens UK Biomethane Plant for Clean Energy -February 28, 2025 at 12:48 am EST - Marketscreener.com
SERD-ified progress: Astrazeneca, others advance in breast cancer - BioWorld Online
AstraZeneca opens biomethane plant in UK to cut emissions - Reuters
Non-Small Cell Lung Cancer Market Set for Significant Growth Across the 7MM During the Study Period (2025-2034) Due to the Rising Novel Therapeutic Options | DelveInsight - GlobeNewswire Inc.
AstraZeneca’s Oral SERD Is First To Succeed In Frontline Breast Cancer - Citeline News & Insights
AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch - BioPharma Dive
AstraZeneca PLC (AZN): One of the Best Vaccine Stocks to Buy According to Hedge Funds - Insider Monkey
Emergency meeting to be held over Liverpool AstraZeneca blow - Liverpool Echo
Astrazeneca Says Interim Data From Breast Cancer Therapy Study Shows Promise -February 26, 2025 at 09:00 am EST - Marketscreener.com
AstraZeneca gets £2bn boost from breast cancer drug readout - Proactive Investors UK
AstraZeneca reports breakthrough in breast cancer treatment - Investing.com India
AstraZeneca therapy improves breast cancer survival in key trial -February 26, 2025 at 06:46 am EST - Marketscreener.com
AstraZeneca breast cancer drug shows positive results, shares up By Investing.com - Investing.com UK
AstraZeneca reports breakthrough in breast cancer treatment By Investing.com - Investing.com UK
AstraZeneca Breast Cancer Pill Delayed Disease Progression - Bloomberg
AstraZeneca: positive data in breast cancer -February 26, 2025 at 04:16 am EST - Marketscreener.com
AstraZeneca's camizestrant shows promise in breast cancer trial - ShareCast
AstraZeneca's Breast Cancer Treatment Shows Upbeat Interim Results in Ongoing Trial - Marketscreener.com
AstraZeneca therapy improves survival in late-stage breast cancer trial - Reuters.com
AstraZeneca therapy improves survival in late-stage breast cancer trial -February 26, 2025 at 02:37 am EST - Marketscreener.com
Astrazeneca, Vertex, Axsome secure US FDA approvals in January - BioWorld Online
AstraZeneca Pharma India ropes in Harish Dash as Senior Director, Commercial IT & Digital - Medical Dialogues
Constipation Treatment Market Is Booming Worldwide 2025-2032 | - openPR
AstraZeneca therapy improves survival in late-stage breast cancer trial -February 26, 2025 at 02:47 am EST - Marketscreener.com
AstraZeneca PLC (AZN): A High Growth Mega Cap Stock You Can Buy and Hold for the Next 5 Years - MSN
Asia Deal Watch: AstraZeneca Buys FibroGen’s Chinese Subsidiary - Citeline News & Insights
AstraZeneca PLC Investors: Please contact the Portnoy Law - GlobeNewswire
AstraZeneca PLC Investors: Please contact the Portnoy Law Firm to recover your losses. February 21, 2025 Deadline to file Lead Plaintiff Motion - TradingView
AstraZeneca PLC (LON:AZN) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
AstraZeneca PLC (AZN): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts - Insider Monkey
AstraZeneca PLC Securities Fraud Class Action Lawsuit - GlobeNewswire
AstraZeneca receives A1 rating upgrade from Moody's, outlook stable By Investing.com - Investing.com Australia
AstraZeneca receives A1 rating upgrade from Moody's, outlook stable - Investing.com
Moody's Lifts AstraZeneca's Ratings, Revises Outlook to Stable -February 21, 2025 at 11:51 am EST - Marketscreener.com
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca - Business Wire
Levi & Korsinsky Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming DeadlineAZN - ACCESS Newswire
2025-02-21 | FINAL REMINDER AZN DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts AstraZeneca PLC Investors to Participate in the Class Action Lawsuit | NDAQ:AZN | Press Release - Stockhouse Publishing
Meitav Investment House Ltd. Buys 205,000 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Atria Wealth Solutions Inc. Acquires 6,970 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Bryn Mawr Capital Management LLC Has $1.03 Million Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca PLC Investors: Please contact the Portnoy Law Firm t - WICZ
AstraZeneca Target of Unusually Large Options Trading (NASDAQ:AZN) - Defense World
AZN Deadline: AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit Filed by The Rosen Law Firm - PR Newswire
AstraZeneca PLC (AZN): Among the Best Global Stocks to Buy According to Hedge Funds - Insider Monkey
Final Deadline for the AstraZeneca PLC Securities LawsuitContact the DJS Law Group to Discuss Your RightsAZN - The Malaysian Reserve
2025-02-20 | AstraZeneca PLC Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationAZN | NDAQ:AZN | Press Release - Stockhouse Publishing
FibroGen sells China unit to AstraZeneca for $160m - Pharmaceutical Technology
AstraZeneca Stock: Strategic Expansion in Chinese Market Intensifies - sharewise
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million - Benzinga India
US CDC vaccine advisory meeting to be postponed, Stat News reports -February 20, 2025 at 01:06 pm EST - Marketscreener.com
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):